tbuckley/cabot-search huggingface dataset:
Eye of the Storm
Authors: Beverly Greenspan
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment of presumed prolactinoma by transsphenoidal operation: early and late results.
Authors: J A Thomson, G M Teasdale, D Gordon, D C McCruden, D L Davies
Journal: BMJ (1985)

Seventy seven patients who were presumed to have a prolactinoma on the basis of biochemical findings underwent transsphenoidal operation between October 1977 and September 1983. Sixty one patients were found to have a microadenoma, and hyperprolactinaemia was cured in 46 of these, amenorrhoea in 39 (80% of those with the symptom), galactorrhoea in 32 (80%), and infertility in 31 (82%). Four of eight patients found to have a macroadenoma were also satisfactorily treated with surgery. Two patients had a lesion other than a prolactinoma, and in six a tumour could not be found at operation; four of these last eight patients had a normal serum prolactin concentration after operation. Recurrent hyperprolactinaemia was rare, occurring in only three patients in the series overall; among the 32 patients followed up for more than five years only two of the 22 whose operation had initially been successful developed recurrent hyperprolactinaemia.
A Pepsi Challenge
Authors: Brian Olshansky
Journal: New England Journal of Medicine (1999)

To the Editor: A 72-year-old man with recurrent dizziness, confusion, and syncope told an internist that cold, carbonated beverages caused him to feel strange, dizzy, and confused and might have triggered several episodes over a one-year study period. A carotid Doppler study, 24-hour Holter monitor, cranial magnetic resonance imaging scan, computed tomographic scan, and echocardiogram were unremarkable. An electroencephalogram showed diffuse slowing. Phenytoin was given but provided no improvement. Another internist evaluated the patient's condition and ordered a treadmill exercise test and another magnetic resonance imaging scan, which were negative. A cardiologist was consulted, and the results of a tilt-table . . .
1001. Knockdown of CXCR4 Expression Sufficient for Blocking HIV-1-Infection Requires Combinatorial Intrabody and siRNA Mediated HIV-1 Vector Gene Delivery
Authors: Christina H. Swan, Mario P. Tschan, Carlos F. Barbas, Bruce E. Torbett
Journal: Molecular Therapy (2005)

A number of chemokine receptors have been shown to facilitate HIV-1 entry in tissue culture, however, only CCR5 and CXCR4 have been convincingly demonstrated to be the relevant chemokine co-receptors. Mechanisms based on targeting CCR5 or CXCR4 to prevent viral entry may prove to be beneficial for cellular protection against HIV-1 infection and provide a clinical benefit. In contrast to CCR5, targeting CXCR4 by conventional siRNA or intrabody gene delivery has proven insufficient to promote adequate protection. To develop vectors that protect CD4 T-cells from X4 tropic infection, a SIN HIV-1 vector containing CXCR4 siRNA and intrabody genes in combination has been generated, termed the CGW-siX4/X4i vector. When transduced into primary CD4 T-cells, CXCR4 cell surface expression decreased 7-fold as determined by mean fluorescence intensity (MFI), compared to the vectors containing only intrabody, 2-fold or siRNA, 2-fold. These results confirm expression of the intrabody and siRNA genes from the same vector provides additive effects for CXCR4 knockdown.
Double‐blind, placebo‐controlled, dose‐ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber
Authors: W. Meyer, A. Narkus, A. M. Salapatek, D. Häfner
Journal: Allergy (2013)

Abstract Background Recombinant allergens offer a tool for improving specific immunotherapy ( SIT ). Objective To find the optimal dose of a new hypoallergenic folding variant of recombinant Bet v 1 (rBet v 1‐FV) as SIT for patients with birch pollen allergy. Methods Before SIT , thirty‐seven adult patients were exposed for eight hours in an environmental exposure chamber ( EEC ) to birch pollen at an average concentration of 3500 ± 500 grains/m 3 , then randomized to four maintenance dose groups of rBet v 1‐FV and one placebo group: 20 μg ( n = 7), 80 μg ( n = 8), 160 μg ( n = 7), 320 μg ( n = 8), and placebo ( n = 7). Patients were treated for 10 weeks with weekly injections and then re‐exposed in the EEC . The optimal dose for SIT was assessed using efficacy results from the EEC , IgG responses, and tolerability. Results Thirty‐six patients were evaluable for efficacy assessment. The total symptom score significantly decreased in all active groups compared with placebo (−18.8% for placebo patients; −71.9%, P = 0.0022 for 20 μg; −75.6%, P = 0.0007 for 80 μg; −81.8%, P = 0.0009 for 160 μg; −78.3%, P = 0.0003 for 320 μg). IgG 1 increased significantly in all active groups compared to placebo. All four active doses were well tolerated, no serious adverse event occurred; two G rade II reactions, according to EAACI classification, were observed, one in each of the 160‐ and 320‐μg groups. Conclusions Considering efficacy, immunological response, and tolerability, a maintenance dose of 80 μg of rBet v 1‐FV appears to be the ideal dose for allergen immunotherapy in birch pollen allergic patients.
NAME BADGES FOR NURSES AND STAFF
Authors: Morris Leff
Journal: JAMA (1926)

<h3>To the Editor:</h3> —It is an accepted fact that a personal relationship between patient and physician, and patient and nurse, is an important factor in aiding in the recovery of the patient. In order to obtain that personal relationship, it is necessary that the physician and the nurse should not consider the patient only as a case but as a human being. In order to add to the personal touch, I have inaugurated at our hospital name badges for the nurses. Each nurse has a badge with her name printed on it, which she wears while on duty. This serves as an introduction between the nurse and the patient, and helps to establish a more confident feeling in the patient toward the nurse. It also helps the physicians to know the nurses that are to carry out their orders. It aids the supervisor in knowing her nurses and remembering their
Serodiagnosis of Pregnancy
Authors: S. L. Cherry
Journal: JAMA (1913)

<h3>To the Editor:</h3> —The main difficulty so far in the serodiagnosis of pregnancy has been the danger of bacterial contamination. I have had no trouble since using the following precautions: 1. The prepared placenta is kept in distilled water containing a few drops of chloroform and a layer of toluol. Just before use a small piece of placenta is removed and boiled in a small quantity of distilled water. This insures sterility and also removes any chloroform present. 2. When ready the dialyzers are lowered into ordinary hydrometer jars without lips. After toluol has been added to the dialyze and the water, the jar is tightly corked. There is almost no evaporation. 3. Immediately after use the thimbles are thoroughly washed in running tap-water and drained by inverting them on a sheet of filter-paper. Just before use they are again washed and boiled in distilled water for three minutes. [Comment
A Randomised British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma
Authors: D.C. Linch, P. Smith, B.W. Hancock, P.J. Hoskin, D.C. Cunningham, A.C. Newland, D. Milligan, P.A. Stevenson, J.K. Wood, K.A. Maclennan, B.Vaughan Hudson, G.Vaughan Hudson, W.M. Gregory
Journal: Annals of Oncology (2000)
Researchers have failed to ease access to patients' data for research
Authors: C. Dyer
Journal: BMJ (2009)

Researchers seem to have lost the battle for “bureaucratic” controls to be lifted on the use of data in which patients are identifiable.

The government is to go ahead with setting up research “safe havens,” bodies such as the NHS Information Centre that will be allowed to collect identifiable patient data, process it into anonymised and pseudonymised data, and provide data in both identifiable and non-identifiable form for use in research.

But the National Information Governance Board for Health and Social Care believes that under current legislation the safe havens will need the approval of its ethics and confidentiality committee to collect, store, and process identifiable data …
Is Alzheimer's disease an apolipoprotein E amyloidosis?
Authors: T. Wisniewski, M. Lalowski, A. Golabek, B. Frangione, T. Vogel
Journal: The Lancet (1995)

The presence of the apolipoprotein E4 allele has been identified as a major risk factor for late-onset Alzheimer's disease. Apolipoprotein E has also been found immunohistochemically in Alzheimer's disease lesions. We biochemically isolated amyloid β from senile plaques and found that a carboxyl-terminal fragment (residues 216-299) of apolipoprotein E co-purified. In vitro this fragment from recombinant apolipoprotein E could form amyloid-like fibrils, which were Congo-red positive. Thus senile plaques may contain both amyloid β and apolipoprotein E amyloid fibrils.
Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation†
Authors: Yuxia Zhang, Ping Xu, Kyungtae Park, Yunhee Choi, David D. Moore, Li Wang
Journal: Hepatology (2008)

The small heterodimer partner (SHP; NROB2), a member of the nuclear receptor superfamily, contributes to the biological regulation of several major functions of the liver. However, the role of SHP in cellular proliferation and tumorigenesis has not been investigated before. Here we report that SHP negatively regulates tumorigenesis both in vivo and in vitro. SHP−/− mice aged 12 to 15 months old developed spontaneous hepatocellular carcinoma, which was found to be strongly associated with enhanced hepatocyte proliferation and increased cyclin D1 expression. In contrast, overexpressing SHP in hepatocytes of SHP-transgenic mice reversed this effect. Embryonic fibroblasts lacking SHP showed enhanced proliferation and produced increased cyclin D1 messenger RNA and protein, and SHP was shown to be a direct negative regulator of cyclin D1 gene transcription. The immortal SHP−/− fibroblasts displayed characteristics of malignant transformed cells and formed tumors in nude mice. Conclusion: These results provide first evidence that SHP plays tumor suppressor function by negatively regulating cellular growth. (HEPATOLOGY 2008.)
Fluconazole Prophylaxis in Patients with Leukemia
Authors: Drew J. Winston
Journal: Annals of Internal Medicine (1993)

Letters1 November 1993Fluconazole Prophylaxis in Patients with LeukemiaDrew J. Winston, MDDrew J. Winston, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-119-9-199311010-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:In our multicenter trial [1] involving 257 patients, we did not observe a significant increase in the incidence of colonization or infection by either C. krusei or T. glabrata in patients with acute leukemia who were receiving prophylactic fluconazole (400 mg/d). Similar results were found in the randomized, placebo-controlled trial of prophylactic fluconazole in 357 patients undergoing bone marrow transplantation [2]. The single case report and two small clinical trials of low-dose prophylactic fluconazole (50 or 200 mg/d) referred to by Drs. Akiyama, Sakamaki, and Onozawa also did not prove that prophylactic fluconazole enhances the risk for infection ...References1. Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med. 1993; 118: 495-503. Google Scholar2. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaiser H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992; 326:845-51. Google Scholar3. Stark A, Dale B, Toolis F. Fluconazole prophylaxis in neutropenic patients (Letter). Br J Haematol. 1993; 83:348. Google Scholar4. Meunier F, Aoun M, Janssens M, Dekoster C, Paesmans M. Chemoprophylaxis of fungal infections in granulocytopenic patients using fluconazole vs. oral amphotericin B. Drug Invest. 1991; 3:258-65. Google Scholar5. Rozenberg-Arska M, Dekker AW, Branger J, Verhoef J. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukemia. J Antimicrob Chemother. 1991; 27:369-76. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byRegional Variations in the Further Management of Neutropenic Patients already Receiving Empirical Antimicrobial TherapyOne stop mycology 1 November 1993Volume 119, Issue 9Page: 951-952KeywordsAmphotericinBone marrow transplantationCandidaClinical trial reportingClinical trialsDecision makingMortalityProphylaxisRetrospective studiesSafety Issue Published: 1 November 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Inhibition of ascorbic-acid-induced depolymerization of hyaluronic acid by ceruloplasmin in synovial fluid.
Authors: W Niedermeier
Journal: Annals of the Rheumatic Diseases (1968)

Depolymerization as measured by Changes in SpecificViscosity.-Allexperiments involving the effect of ascor- bic acid on viscosity of purified hyaluronic acid were copyright.
Experimental Cardiac Hypertrophy
Authors: Barry L. Fanburg
Journal: New England Journal of Medicine (1970)

STUDIES on the process by which enlargement of the heart occurs1 2 3 4 have been aided by developments in molecular biology. Recent reviews in this journal have dealt with the information available on liver regeneration and compensatory growth of the kidney.5 , 6 As with the liver and the kidney, there is still a considerable lack of understanding of the molecular changes that occur during cardiac enlargement. Cardiac muscle is technically more difficult than liver to study in this respect because of the resistance of the tissue to fractionation, the preponderance of contractile proteins and the paucity of protein-synthesizing structures. Nevertheless, information has been . . .
A physiological evaluation of professional soccer players.
Authors: P. B. Raven, L. R. Gettman, M. L. Pollock, K. H. Cooper
Journal: British Journal of Sports Medicine (1976)

The purpose of this study was to evaluate the physiological functions of a professional soccer team in the North American Soccer League (NASL). Eighteen players were evaluated on cardiorespiratory function, endurance performance, body composition, blood chemistry, and motor fitness measures near the end of their competitive season. The following means were observed: age, 26 yrs; height, 176 cm; weight 75.5 kg; resting heart rate, 50 beats/min; maximum heart rate (MHR), 188 beats/min; maximum oxygen intake (VO2 max), 58.4 ml/kg-min-1; maximum ventilation (VEmax BTPS), 154 L/min; body fat, 9.59%; 12-min run, 1.86 miles; and Illinois agility run, 15.6 secs. Results on resting blood pressure, serum lipids, vital capacity, flexibility, upper body strength, and vertical jump tests were comparable to values found for the sedentary population. Comparing the results with previously collected data on professional American Football backs indicated that the soccer players were shorter; lighter in body weight; higher in VO2 max (4 ml/kg-min-1) and body fat (1.8%); and similar in MHR, VE max, and VC. The 12-min run scores were similar to the initial values observed for the 1970 Brazilian World Cup Team. The agility run results were superior to data collected from other groups. Their endurance capabilities, agility, and low percent of body fat clearly differentiate them from the sedentary population and show them to be similar to that of professional American football backs.
Drug points: Parotid swelling and terbinafine
Authors: J K Torrens, P H McWhinney
Journal: BMJ (1998)

Terbinafine is an effective antimycotic agent of the allylamine type which inhibits the enzyme squalene epoxidase.1 It is generally well tolerated, although taste disturbance occurs in about 1 in 800 cases2 and various skin reactions and hepatobiliary effects have been noted.3

A 38 year old man presented with a painful right ear 15 days after taking terbinafine 250 mg daily for tinea cruris. On examination a …
Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival
Authors: Adrian Wiestner, Mahsa Tehrani, Michael Chiorazzi, George Wright, Federica Gibellini, Kazutaka Nakayama, Hui Liu, Andreas Rosenwald, H. Konrad Muller-Hermelink, German Ott, Wing C. Chan, Timothy C. Greiner, Dennis D. Weisenburger, Julie Vose, James O. Armitage, Randy D. Gascoyne, Joseph M. Connors, Elias Campo, Emilio Montserrat, Francesc Bosch, Erlend B. Smeland, Stein Kvaloy, Harald Holte, Jan Delabie, Richard I. Fisher, Thomas M. Grogan, Thomas P. Miller, Wyndham H. Wilson, Elaine S. Jaffe, Louis M. Staudt
Journal: Blood (2007)
Timing and velocity of ejection as major determinants of end-systolic pressure in isolated rabbit hearts.
Authors: A Ezzaher, T el Ouazzani, B Crozatier
Journal: Circulation (1994)

BACKGROUND Systolic shortening is known to produce muscle deactivation. The present study was designed to analyze whether the velocity and the timing of ejection play a role on end-systolic pressure-volume relations (ESPVR). METHODS AND RESULTS In isolated rabbit hearts, left ventricular pressure and volume were recorded and digitized, and left ventricular volume was controlled by a servosystem (4-millisecond cycles) to alter the timing of ejection. A significant deficit in end-systolic pressure was observed when ejection was late in systole with respect to earlier ejection. This was associated with a significantly reduced end-systolic elastance. End-systolic pressure of beats with slow ejection was intermediate between that of the beats with early ejection and that of beats with late ejection with a significantly increased end-systolic volume compared with beats with early rapid ejection. The same results were obtained with hypertrophied hearts (abdominal aortic stenosis). Pressure-volume loop areas were significantly increased in beats with slow ejections and with rapid delayed ejections versus early rapid ejections. No change in the positive peak of dP/dt was observed when the timing and the velocity of ejection were modified. CONCLUSIONS ESPVR is modified by the ejection profile, with a decreased end-systolic pressure and an increased pressure-volume loop area related to the velocity and the amount of shortening during the end-systolic phase. These indices of ventricular function thus must be used with caution when the timing of ejection is altered, and the end-diastolic volume-peak dP/dt relation may be a better index of ventricular function.
Fluoxetine Versus Placebo in Advanced Cancer Outpatients
Authors: Carol Alliot
Journal: Journal of Clinical Oncology (2003)

than requiring another single agent or even multiagent chemotherapy.It is the Charing Cross group that first drew attention to the incidence of leukemia following combination chemotherapy with etoposide, so it is agreed among the trophoblastic community that multiagent chemotherapy is preferably avoided if single-agent chemotherapy will do the job.The best way to achieve that goal is to use the same single agent in a 5-day course, and that procedure has 60% to 70% effectiveness.The alternate day methotrexate/leucovorin protocol has as high a failure rate as pulsed therapy with either methotrexate or actinomycin.All these drugs are cycle specific, and it is time that the trophoblastic community accepted that there is a chance the primary therapy may not be effective.The Society of Gynecologic Oncologists has advocated that the conflict in whether clinical trophoblastic disease requiring chemotherapy on the basis of human chorionic gonadotropin persistence is pathologically benign or malignant is best avoided by use of the term "trophoblastic neoplasia."The authors do not abide by this rule either.It is a pity that one of the leading institutions treating trophoblastic neoplasia will not abide by the very rules it helped create.
Air pollution and retained particles in the lung.
Authors: M Brauer, C Avila-Casado, T I Fortoul, S Vedal, B Stevens, A Churg
Journal: Environmental Health Perspectives (2001)

Epidemiologic evidence associates particulate air pollution with cardiopulmonary morbidity and mortality. The biological mechanisms underlying these associations and the relationship between ambient levels and retained particles in the lung remain uncertain. We examined the parenchymal particle content of 11 autopsy lungs from never-smoking female residents of Mexico City, a region with high ambient particle levels [3-year mean PM(10) (particulate matter < or = 10 microm in aerodynamic diameter)= 66 microg/m(3)], and 11 control residents of Vancouver, British Columbia, Canada, a region with relatively low levels (3-year mean PM(10) = 14 microg/m(3). Autopsy lungs were dissolved in bleach and particles were identified and counted by analytical electron microscopy. Total particle concentrations in the Mexico City lungs were significantly higher [geometric mean = 2,055 (geometric SD = 3.9) x 10(6) particles/g dry lung vs. 279 (1.8) x 10(6) particles/g dry lung] than in lungs from Vancouver residents. Lungs from Mexico City contained numerous chain-aggregated masses of ultrafine carbonaceous spheres, some of which contained sulfur, and aggregates of ultrafine aluminum silicate. These aggregates made up an average of 25% of the total particles by count in the lungs from Mexico City, but were only rarely seen in lungs from Vancouver. These observations indicate for the first time that residence in a region with high levels of ambient particles results in pulmonary retention of large quantities of fine and ultrafine particle aggregates, some of which appear to be combustion products.